Literature DB >> 15158749

Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics.

Richard D Sontheimer1.   

Abstract

Skin disease can significantly affect the quality of life of patients suffering from rheumatic diseases. In addition, important relationships exist between the cutaneous and systemic manifestations of rheumatic disease. It is thus important for practicing rheumatologists to have a solid working understanding of the subject of rheumatic skin disease. Unfortunately, it is not possible within the scope of this chapter to provide a comprehensive overview of the recognition and management of all of the cutaneous manifestations of lupus erythematosus (LE), much less those of dermatomyositis (DM)/polymyositis and scleroderma/systemic sclerosis (SSc) as well. As can be seen in in the text, the cutaneous manifestations of polygenic autoimmune disorders such as LE can be as heterogeneous clinically as are its systemic manifestations. This discussion will therefore focus on recent key developments concerning the diagnosis and management of the more common skin changes that the practicing rheumatologist is likely to encountered in the three major rheumatic diseases: LE, DM and SSc.

Entities:  

Mesh:

Year:  2004        PMID: 15158749     DOI: 10.1016/j.berh.2004.03.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  10 in total

1.  Tumor necrosis factor inhibitor-associated dermatomyositis.

Authors:  Rachel Klein; Misha Rosenbach; Ellen J Kim; Brian Kim; Victoria P Werth; Jonathan Dunham
Journal:  Arch Dermatol       Date:  2010-07

2.  Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway.

Authors:  Guo-Min Deng; Lena Liu; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

3.  Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis.

Authors:  Spyros Aslanidis; Athina Pyrpasopoulou; Nikoleta Kartali; Chryssanthos Zamboulis
Journal:  Clin Rheumatol       Date:  2006-05-31       Impact factor: 2.980

Review 4.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

5.  The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.

Authors:  A M Huber; E M Dugan; P A Lachenbruch; B M Feldman; M D Perez; L S Zemel; C B Lindsley; R M Rennebohm; C A Wallace; M H Passo; A M Reed; S L Bowyer; S H Ballinger; F W Miller; L G Rider
Journal:  Rheumatology (Oxford)       Date:  2007-10       Impact factor: 7.580

6.  Basal Activation of Type I Interferons (Alpha2 and Beta) and 2'5'OAS Genes: Insights into Differential Expression Profiles of Interferon System Components in Systemic Sclerosis.

Authors:  Danilo Bretas de Oliveira; Gabriel Magno de Freitas Almeida; Antônio Carlos Martins Guedes; Flávia Patrícia Sena Teixeira Santos; Claudio Antônio Bonjardim; Paulo César Peregrino Ferreira; Erna Geessien Kroon
Journal:  Int J Rheumatol       Date:  2011-11-01

7.  Small lymphocytic lymphoma with florid perniosis-like features: a case report.

Authors:  Taylor M Morris; Rosetta Mazzola; Brian Berry; Douglas Sawyer; David L Saltman
Journal:  BMC Dermatol       Date:  2015-07-23

Review 8.  Cutaneous lupus erythematosus: An update.

Authors:  Carina M Grönhagen; Filippa Nyberg
Journal:  Indian Dermatol Online J       Date:  2014-01

9.  Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis.

Authors:  Takuya Hirai; Keigo Ikeda; Hiroshi Tsushima; Maki Fujishiro; Kunihiro Hayakawa; Yuko Yoshida; Shinji Morimoto; Ken Yamaji; Yoshinari Takasaki; Kenji Takamori; Naoto Tamura; Iwao Sekigawa
Journal:  Inflamm Regen       Date:  2018-01-08

10.  Hemophagocytic Syndrome Complicated with Dermatomyositis Controlled Successfully with Infliximab and Conventional Therapies.

Authors:  Yoji Komiya; Tetsuya Saito; Fumitaka Mizoguchi; Hitoshi Kohsaka
Journal:  Intern Med       Date:  2017-12-01       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.